Affected female carriers of MTM1 mutations display a wide spectrum of clinical and pathological involvement: delineating diagnostic clues

Carregando...
Imagem de Miniatura
Citações na Scopus
43
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
BIANCALANA, Valerie
SCHEIDECKER, Sophie
MIGUET, Marguerite
LAQUERRIERE, Annie
ROMERO, Norma B.
STOJKOVIC, Tanya
MERCIER, Sandra
VOERMANS, Nicol
TANNER, Laura
Citação
ACTA NEUROPATHOLOGICA, v.134, n.6, p.889-904, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
X-linked myotubular myopathy (XLMTM), a severe congenital myopathy, is caused by mutations in the MTM1 gene located on the X chromosome. A majority of affected males die in the early postnatal period, whereas female carriers are believed to be usually asymptomatic. Nevertheless, several affected females have been reported. To assess the phenotypic and pathological spectra of carrier females and to delineate diagnostic clues, we characterized 17 new unrelated affected females and performed a detailed comparison with previously reported cases at the clinical, muscle imaging, histological, ultrastructural and molecular levels. Taken together, the analysis of this large cohort of 43 cases highlights a wide spectrum of clinical severity ranging from severe neonatal and generalized weakness, similar to XLMTM male, to milder adult forms. Several females show a decline in respiratory function. Asymmetric weakness is a noteworthy frequent specific feature potentially correlated to an increased prevalence of highly skewed X inactivation. Asymmetry of growth was also noted. Other diagnostic clues include facial weakness, ptosis and ophthalmoplegia, skeletal and joint abnormalities, and histopathological signs that are hallmarks of centronuclear myopathy such as centralized nuclei and necklace fibers. The histopathological findings also demonstrate a general disorganization of muscle structure in addition to these specific hallmarks. Thus, MTM1 mutations in carrier females define a specific myopathy, which may be independent of the presence of an XLMTM male in the family. As several of the reported affected females carry large heterozygous MTM1 deletions not detectable by Sanger sequencing, and as milder phenotypes present as adult-onset limb-girdle myopathy, the prevalence of this myopathy is likely to be greatly underestimated. This report should aid diagnosis and thus the clinical management and genetic counseling of MTM1 carrier females. Furthermore, the clinical and pathological history of this cohort may be useful for therapeutic projects in males with XLMTM, as it illustrates the spectrum of possible evolution of the disease in patients surviving long term.
Palavras-chave
MTM1, X-linked myotubular myopathy, Centronuclear myopathy, Congenital myopathy, X inactivation
Referências
  1. Agrawal PB, 2014, AM J HUM GENET, V95, P218, DOI 10.1016/j.ajhg.2014.07.004
  2. ALLEN RC, 1992, AM J HUM GENET, V51, P1229
  3. Amburgey K, 2013, NEUROMUSCULAR DISORD, V23, P214, DOI 10.1016/j.nmd.2012.11.010
  4. Amos-Landgraf JM, 2006, AM J HUM GENET, V79, P493, DOI 10.1086/507565
  5. Bartsch O, 1999, CYTOGENET CELL GENET, V85, P310, DOI 10.1159/000015284
  6. Bevilacqua JA, 2011, NEUROPATH APPL NEURO, V37, P271, DOI 10.1111/j.1365-2990.2010.01149.x
  7. Bevilacqua JA, 2009, ACTA NEUROPATHOL, V117, P283, DOI 10.1007/s00401-008-0472-1
  8. Biancalana V, 2003, HUM GENET, V112, P135, DOI 10.1007/s00439-002-0869-1
  9. Biancalana V, 2012, EUR J HUM GENET, V20, DOI 10.1038/ejhg.2012.91
  10. Bitoun M, 2005, NAT GENET, V37, P1207, DOI 10.1038/ng1657
  11. Bohm J, 2014, BRAIN, V137, P3160, DOI 10.1093/brain/awu272
  12. Carrel L, 1996, AM J MED GENET, V64, P27, DOI 10.1002/(SICI)1096-8628(19960712)64:1<27::AID-AJMG3>3.0.CO;2-O
  13. Casar-Borota O, 2015, NEUROMUSCULAR DISORD, V25, P345, DOI 10.1016/j.nmd.2015.01.001
  14. Ceyhan-Birsoy O, 2013, NEUROLOGY, V81, P1205, DOI 10.1212/WNL.0b013e3182a6ca62
  15. Childers MK, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007523
  16. Cowling BS, 2014, J CLIN INVEST, V124, P1350, DOI 10.1172/JCI71206
  17. DAHL N, 1995, AM J HUM GENET, V56, P1108
  18. deGouyon BM, 1997, HUM MOL GENET, V6, P1499, DOI 10.1093/hmg/6.9.1499
  19. Drouet A, 2008, REV NEUROL-FRANCE, V164, P169, DOI 10.1016/j.neurol.2007.08.008
  20. Dubowitz V, 2013, MUSCLE BIOPSY PRACTI
  21. Fattori F, 2015, J NEUROL, V262, P1728, DOI 10.1007/s00415-015-7757-9
  22. Flex E, 2002, NEUROMUSCULAR DISORD, V12, P501, DOI 10.1016/S0960-8966(01)00328-5
  23. Fukami M, 2006, NAT GENET, V38, P1369, DOI 10.1038/ng1900
  24. Grogan PM, 2005, NEUROLOGY, V64, P1638, DOI 10.1212/01.WNL.0000160393.99621.D0
  25. Gurgel-Giannetti J, 2012, NEUROMUSCULAR DISORD, V22, P541, DOI 10.1016/j.nmd.2011.12.005
  26. Hagiwara SI, 2013, J PEDIAT GASTROENTER, V60, pe45
  27. Hammans SR, 2000, NEUROMUSCULAR DISORD, V10, P133, DOI 10.1016/S0960-8966(99)00073-5
  28. Hedberg C, 2012, NEUROMUSCULAR DISORD, V22, P244, DOI 10.1016/j.nmd.2011.10.010
  29. Herman GE, 1999, J PEDIATR-US, V134, P206, DOI 10.1016/S0022-3476(99)70417-8
  30. Herman GE, 2002, HUM MUTAT, V19, P114, DOI 10.1002/humu.10033
  31. Hu LJ, 1996, HUM MOL GENET, V5, P139, DOI 10.1093/hmg/5.1.139
  32. Jungbluth H, 2003, NEUROMUSCULAR DISORD, V13, P55, DOI 10.1016/S0960-8966(02)00194-3
  33. Kristiansen M, 2003, NEUROMUSCULAR DISORD, V13, P468, DOI 10.1016/S0960-8966(03)00067-1
  34. Kutchukian C, 2016, P NATL ACAD SCI USA, V113, P14432, DOI 10.1073/pnas.1604099113
  35. Laporte J, 2000, HUM MUTAT, V15, P393, DOI 10.1002/(SICI)1098-1004(200005)15:5<393::AID-HUMU1>3.0.CO;2-R
  36. Laporte J, 1997, HUM MOL GENET, V6, P1505, DOI 10.1093/hmg/6.9.1505
  37. Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175
  38. Laporte J, 2001, ANN NEUROL, V50, P42, DOI 10.1002/ana.1033
  39. Lawlor MW, 2013, HUM MOL GENET, V22, P1525, DOI 10.1093/hmg/ddt003
  40. Liewluck T, 2010, NEUROMUSCULAR DISORD, V20, P801, DOI 10.1016/j.nmd.2010.07.273
  41. McEntagart M, 2002, NEUROMUSCULAR DISORD, V12, P939, DOI 10.1016/S0960-8966(02)00153-0
  42. Motoki T, 2013, NEUROMUSCULAR DISORD, V23, P917, DOI 10.1016/j.nmd.2013.06.008
  43. Neto OA, 2016, PEDIATR NEUROL, V58, P107, DOI 10.1016/j.pediatrneurol.2016.01.023
  44. Nicot AS, 2007, NAT GENET, V39, P1134, DOI 10.1038/ng2086
  45. Oliveira J, 2013, EUR J HUM GENET, V21, P540, DOI 10.1038/ejhg.2012.201
  46. Penisson-Besnier I, 2007, NEUROMUSCULAR DISORD, V17, P180, DOI 10.1016/j.nmd.2006.10.008
  47. Quijano-Roy S, 2011, SEMIN PEDIATR NEUROL, V18, P221, DOI 10.1016/j.spen.2011.10.003
  48. Romero NB, 2010, NEUROMUSCULAR DISORD, V20, P223, DOI 10.1016/j.nmd.2010.01.014
  49. Sabha N, 2016, J CLIN INVEST, V126, P3613, DOI 10.1172/JCI86841
  50. Savarese M, 2016, NEUROMUSCULAR DISORD, V26, P292, DOI 10.1016/j.nmd.2016.02.004
  51. Schara U, 2003, NEUROLOGY, V60, P1363
  52. Smith BK, 2016, MUSCLE NERVE, V53, P214, DOI 10.1002/mus.24899
  53. Soltanzadeh P, 2010, NEUROMUSCULAR DISORD, V20, P499, DOI 10.1016/j.nmd.2010.05.010
  54. Sutton IJ, 2001, NEUROLOGY, V57, P900
  55. Tanner SM, 1999, HUM GENET, V104, P249, DOI 10.1007/s004390050943
  56. Tanner SM, 1999, NEUROMUSCULAR DISORD, V9, P41, DOI 10.1016/S0960-8966(98)00090-X
  57. Tasca G, 2012, EUR J NEUROL, V19, P1256, DOI 10.1111/j.1468-1331.2012.03753.x
  58. Terlizzi JP, 2013, J PEDIATR SURG, V48, pE9, DOI 10.1016/j.jpedsurg.2013.06.014
  59. Tosch V, 2010, NEUROMUSCULAR DISORD, V20, P375, DOI 10.1016/j.nmd.2010.03.015
  60. Trump N, 2012, NEUROMUSCULAR DISORD, V22, P384, DOI 10.1016/j.nmd.2011.11.004
  61. Tsai TC, 2005, NEUROMUSCULAR DISORD, V15, P245, DOI 10.1016/j.nmd.2004.12.005
  62. Viggiano E, 2016, HUM GENET, V135, P685, DOI 10.1007/s00439-016-1666-6
  63. Vincent MC, 1998, J MED GENET, V35, P241, DOI 10.1136/jmg.35.3.241
  64. Wilmshurst JM, 2010, ANN NEUROL, V68, P717, DOI 10.1002/ana.22119
  65. Wu H, 2014, NEURON, V81, P103, DOI 10.1016/j.neuron.2013.10.051